INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of SeaStar Medical Holding Corporation (ICU) on Behalf of InvestorsBusiness Wire • 07/10/24
SeaStar Medical Holding Corporation Investors: Robbins LLP Reminds Shareholders of the SeaStar Medical Holding Corporation (ICU) Class ActionBusiness Wire • 07/10/24
The Law Offices of Frank R. Cruz Announces Investigation of SeaStar Medical Holding Corporation (ICU) on Behalf of InvestorsBusiness Wire • 07/10/24
SEASTAR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against SeaStar Medical Holding Corporation and Encourages Investors to Contact the FirmGlobeNewsWire • 07/10/24
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against SeaStar Medical Holding CorporationGlobeNewsWire • 07/09/24
Shareholder Alert: Robbins LLP Informs Stockholders of the Class Action Filed Against SeaStar Medical Holding Corporation (ICU)GlobeNewsWire • 07/09/24
Rosen Law Firm Urges SeaStar Medical Holding Corporation (ICU, ICUCW) Stockholders with Large Losses to Contact the Firm for Information About Their RightsBusiness Wire • 07/09/24
Class Action Lawsuit Filed on Behalf of SeaStar Medical Holding Corporation (ICU) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the FirmGlobeNewsWire • 07/08/24
SeaStar Medical Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use DeviceGlobeNewsWire • 07/03/24
SeaStar Medical's Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care NephrologyGlobeNewsWire • 06/11/24
SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage CompanyGlobeNewsWire • 06/10/24
Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical's Selective Cytopheretic Device in the Immunomodulation of Excessive InflammationGlobeNewsWire • 06/07/24
SeaStar Medical to Present at the Virtual Emerging Growth Conference on June 12, 2024GlobeNewsWire • 06/06/24
Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical's Selective Cytopheretic Device Who Achieved Transplant EligibilityGlobeNewsWire • 05/22/24
SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart FailureGlobeNewsWire • 04/30/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICUPRNewsWire • 04/28/24
SeaStar Medical Reports 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 04/17/24
SeaStar Medical to Present at the Noble Capital Markets' Emerging Growth Virtual Healthcare Equity ConferenceGlobeNewsWire • 04/11/24
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17GlobeNewsWire • 03/27/24
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric PatientsGlobeNewsWire • 03/12/24
SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024GlobeNewsWire • 03/11/24
Manuscript Discussing the Benefit of SeaStar Medical's Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart FailureGlobeNewsWire • 02/27/24
FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical's Selective Cytopheretic Device for Pediatric Acute Kidney InjuryGlobeNewsWire • 02/22/24
